DoW Toxic Exposures Clinical Trial Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The FY26 Toxic Exposures Research Program Clinical Trial Award supports clinical trials aimed at improving the prevention, treatment, or management of health issues related to military toxic exposures. This program funds a wide range of clinical trials, from early-stage proof-of-concept studies to large-scale pragmatic trials designed to test efficacy in relevant patient groups. The goal is to advance scientific understanding and clinical applications that address diseases or symptoms stemming from toxic exposures experienced during military service. A key feature of this award is the Partnering Principal Investigator Option, which encourages interdisciplinary collaboration by allowing two principal investigators to jointly lead the research effort, with each receiving separate funding awards. This option is intended to foster partnerships, for example between clinicians and research scientists, to enhance the impact and accelerate the translation of research findings into clinical practice beyond what could be achieved independently. The program is managed by the Department of the Army under the Department of Defense.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
